Assembly Biosciences, Inc (ASMB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ASMB SEC filings page.
Assembly Biosciences, Inc (ASMB) reported $74.8M in revenue over the twelve months to Jun 30, 2026, up 125.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 brought much more revenue, but cash use still outpaced reported earnings in this development-led business.
Operating loss narrowed to$12.1M in FY2025 as revenue more than doubled from FY2024, but operating cash flow remained-$41.1M . Against a net loss of$6.1M , that gap means accounting improvement has not yet become cash improvement.
R&D reached
FY2025 financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Assembly Biosciences, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Assembly Biosciences, Inc held $248.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $41.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Assembly Biosciences, Inc scores 72/100 among other emerging companies.
Assembly Biosciences, Inc had 16M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Assembly Biosciences, Inc scores 15/100 among other emerging companies.
Assembly Biosciences, Inc spent $64.8M on research and development in fiscal year 2025, which was 76.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Assembly Biosciences, Inc scores 95/100 among other emerging companies.
Assembly Biosciences, Inc reported revenue of $72.3M in fiscal year 2025, against $28.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Assembly Biosciences, Inc scores 92/100 among other emerging companies.
Not available for Assembly Biosciences, Inc, and counted as zero in the overall score.
Assembly Biosciences, Inc's cash, cash equivalents and investments came to $248.1M at the end of fiscal year 2025, against $50.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Assembly Biosciences, Inc scores 89/100 among other emerging companies.
Assembly Biosciences, Inc scores 1.98, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($458.9M) relative to total liabilities ($50.8M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Assembly Biosciences, Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Assembly Biosciences, Inc reported a net loss of $6.1M while operations used $41.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Assembly Biosciences, Inc generated $13.4M in revenue in Q2 2026. This represents an increase of 38.9% from the same quarter a year earlier. Against the prior quarter it is up 62.8%.
Assembly Biosciences, Inc's EBITDA was -$6.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.8% from the same quarter a year earlier. Against the prior quarter it is up 44.3%.
Assembly Biosciences, Inc reported -$3.9M in net income in Q2 2026. This represents an increase of 62.2% from the same quarter a year earlier. Against the prior quarter it is up 57.5%.
Assembly Biosciences, Inc earned -$0.20 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 63.0%.
Cash & Balance Sheet
Assembly Biosciences, Inc recorded an outflow of $15.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 7.6% from the same quarter a year earlier. Against the prior quarter it is up 30.0%.
Assembly Biosciences, Inc held $32.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Assembly Biosciences, Inc's operating margin was -47.4% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Assembly Biosciences, Inc's net profit margin was -28.8% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Assembly Biosciences, Inc's ROE was -1.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 55.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.3 percentage points.
Not reported for Q2 2026.
Capital Allocation
Assembly Biosciences, Inc invested $14.9M in research and development in Q2 2026. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.
Assembly Biosciences, Inc reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
ASMB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.4M+38.9% | $8.2M-12.8% | $42.5M+477.3% | $10.8M+57.6% | $9.6M+12.8% | $9.4M+62.8% | $7.4M | $6.8M |
| R&D Expenses | $14.9M-7.5% | $14.9M+0.3% | $17.3M+20.8% | $16.6M+22.7% | $16.1M-0.8% | $14.9M+25.0% | $14.3M | $13.5M+24.9% |
| SG&A Expenses | $4.8M+4.5% | $4.7M+3.9% | $5.4M+17.6% | $5.1M+18.6% | $4.6M+2.6% | $4.5M-2.7% | $4.6M | $4.3M+1.5% |
| Operating Income | -$6.3M+42.8% | -$11.4M-14.4% | $19.8M+271.7% | -$10.9M+0.7% | -$11.1M+9.1% | -$9.9M+7.3% | -$11.5M | -$11.0M+27.2% |
| EBITDA | -$6.3M+42.8% | -$11.3M-14.5% | $19.8M+272.4% | -$10.9M+0.7% | -$11.1M+9.1% | -$9.9M+7.4% | -$11.5M | -$10.9M+26.8% |
| Income Tax | N/A | N/A | N/A | $0 | $0-100.0% | N/A | N/A | $0 |
| Net Income | -$3.9M+62.2% | -$9.1M-3.0% | $22.1M+313.7% | -$9.2M+4.3% | -$10.2M+8.6% | -$8.8M+2.9% | -$10.3M | -$9.6M+33.3% |
| EPS (Basic) | -$0.20+85.0% | -$0.54+53.8% | $2.48+258.0% | -$0.72+52.3% | -$1.33+32.8% | -$1.17+29.5% | -$1.57+11.3% | -$1.51+54.1% |
| EPS (Diluted) | -$0.20 | -$0.54 | $2.48+258.0% | -$0.72 | -$1.33+32.8% | -$1.17+29.5% | -$1.57+11.3% | -$1.51 |
| Diluted Shares (Avg) | 19M | 17M | N/A | 13M | 8M+35.7% | 8M+36.9% | N/A | 6M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ASMB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $330.8M+309.5% | $235.5M+137.8% | $257.6M+116.2% | $240.0M+139.4% | $80.8M-30.0% | $99.0M-17.4% | $119.2M-12.9% | $100.3M+94.2% |
| Current Assets | $328.0M+323.4% | $232.6M+143.5% | $254.5M+120.4% | $236.8M+141.1% | $77.5M-31.4% | $95.5M-18.5% | $115.5M-13.7% | $98.2M+97.7% |
| Cash & Equivalents | $32.3M+34.5% | $31.1M+32.9% | $58.5M+52.4% | $22.5M-20.8% | $24.0M+25.0% | $23.4M+24.9% | $38.3M+93.3% | $28.5M+6.7% |
| Short-Term Investments | $288.1M+465.1% | $195.5M+189.1% | $189.7M+157.2% | $210.0M+215.8% | $51.0M-43.4% | $67.6M-28.2% | $73.7M-33.2% | $66.5M+240.1% |
| Accounts Receivable | $822K | $451K | $974K | $912K | N/A | N/A | $0-100.0% | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $25.2M-59.8% | $36.9M-48.7% | $50.8M-40.8% | $57.3M-22.8% | $62.7M-22.3% | $71.9M-17.6% | $85.8M-10.4% | $74.3M+649.0% |
| Current Liabilities | $23.4M-50.4% | $35.0M-24.9% | $48.8M+2.0% | $53.4M+28.2% | $47.3M+14.6% | $46.6M+20.3% | $47.8M+21.9% | $41.6M+483.8% |
| Non-Current Liabilities | $1.7M-88.7% | $1.9M-92.5% | $2.1M-94.6% | $3.9M-88.0% | $15.4M-60.9% | $25.3M-48.0% | $38.0M-32.7% | $32.6M+1072.3% |
| Total Equity | $305.6M+1588.7% | $198.6M+632.0% | $206.8M+519.8% | $182.7M+602.6% | $18.1M-47.8% | $27.1M-16.8% | $33.4M-18.8% | $26.0M-37.7% |
| Retained Earnings | -$845.0M0.0% | -$841.1M-0.8% | -$832.0M-0.7% | -$854.1M-4.7% | -$844.9M-4.8% | -$834.7M-5.0% | -$825.9M-5.1% | -$815.6M-5.3% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ASMB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.5M+7.6% | -$22.1M+5.7% | $14.2M+3598.0% | -$15.1M+0.7% | -$16.8M+2.0% | -$23.4M-27.6% | -$407K-100.6% | -$15.2M-10.1% |
| Depreciation & Amortization | $20K-37.5% | $26K-21.2% | $32K0.0% | $32K-3.0% | $32K0.0% | $33K+3.1% | $32K-61.9% | $33K-71.6% |
| Stock-Based Compensation | $2.4M+189.7% | $1.1M+56.7% | N/A | $1.7M+109.5% | $834K+0.1% | $712K-3.7% | N/A | $797K-29.8% |
| Capital Expenditures | $0 | $19K | $24K | $42K | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Free Cash Flow | -$15.5M+7.6% | -$22.1M+5.6% | $14.2M+3592.1% | -$15.2M+0.5% | -$16.8M+2.1% | -$23.4M-27.5% | -$407K-100.6% | -$15.2M-9.0% |
| Investing Cash Flow | -$92.1M-641.8% | -$5.4M-181.7% | $21.2M+417.0% | -$158.3M-746.3% | $17.0M+232.8% | $6.6M-61.9% | -$6.7M+92.5% | $24.5M+29.7% |
| Financing Cash Flow | $108.7M+30358.0% | $149K-92.2% | $456K-97.3% | $171.9M | $357K-97.1% | $1.9M | $17.0M+84.9% | $0 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ASMB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -47.4% | -138.4% | 46.6% | -100.9% | -115.2% | -105.5% | -156.8% | -160.1% |
| Net Margin | -28.8% | -110.5% | 52.0% | -85.2% | -105.9% | -93.6% | -140.5% | -140.4% |
| Return on Equity | -1.3%+55.1pp | -4.6%+27.9pp | 10.7%+41.7pp | -5.0%+31.9pp | -56.3%-24.2pp | -32.5%-4.7pp | -31.0% | -37.0%-2.4pp |
| Return on Assets | -1.2%+11.5pp | -3.9%+5.0pp | 8.6%+17.3pp | -3.8%+5.8pp | -12.6%-3.0pp | -8.9%-1.3pp | -8.7% | -9.6%+18.3pp |
| Current Ratio | 13.99+12.4x | 6.65+4.6x | 5.22+2.8x | 4.44+2.1x | 1.64-1.1x | 2.05-1.0x | 2.42-1.0x | 2.36-4.6x |
| Debt-to-Equity | 0.08-3.4x | 0.19-2.5x | 0.25-2.3x | 0.31-2.5x | 3.46+1.1x | 2.650.0x | 2.57+0.2x | 2.86+2.6x |
| Asset Turnover | 0.04-0.1x | 0.03-0.1x | 0.16+0.1x | 0.040.0x | 0.120.0x | 0.100.0x | 0.06 | 0.07+0.1x |
| FCF Margin | -115.8% | -269.3% | 33.5%+39.0pp | -140.7% | -174.1% | -248.9% | -5.5% | -222.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Assembly Biosciences, Inc ASMB | FY2025 | $72.3M | -$6.1M | -8.5% | $458.9M | 61/100 |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $307.5M | — |
| Tectonic Therapeutic, Inc. TECX | FY2025 | N/A | N/A | N/A | $440.6M | — |
| Y-mAbs Therapeutics, Inc. YMAB | FY2024 | $87.7M | -$29.7M | -33.8% | $391.2M | 71/100 |
| Benitec Biopharma Inc. BNTC | FY2026 | N/A | -$45.5M | N/A | $313.2M | — |
| Rocket Pharmaceuticals, Inc. RCKT | FY2025 | $0 | -$223.1M | N/A | $281.0M | — |
Where Assembly Biosciences, Inc Ranks
Frequently Asked Questions
What is Assembly Biosciences, Inc's annual revenue?
Assembly Biosciences, Inc (ASMB) reported $72.3M in total revenue for fiscal year 2025. This represents a 153.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Assembly Biosciences, Inc's revenue growing?
Assembly Biosciences, Inc (ASMB) revenue grew by 153.5% year-over-year, from $28.5M to $72.3M in fiscal year 2025.
Is Assembly Biosciences, Inc profitable?
No, Assembly Biosciences, Inc (ASMB) reported a net income of -$6.1M in fiscal year 2025, with a net profit margin of -8.5%.
What is Assembly Biosciences, Inc's EBITDA?
Assembly Biosciences, Inc (ASMB) had EBITDA of -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Assembly Biosciences, Inc's operating margin?
Assembly Biosciences, Inc (ASMB) had an operating margin of -16.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Assembly Biosciences, Inc's net profit margin?
Assembly Biosciences, Inc (ASMB) had a net profit margin of -8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Assembly Biosciences, Inc's return on equity (ROE)?
Assembly Biosciences, Inc (ASMB) has a return on equity of -3.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Assembly Biosciences, Inc's free cash flow?
Assembly Biosciences, Inc (ASMB) recorded an outflow of $41.2M in free cash flow during fiscal year 2025. This represents a 19.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Assembly Biosciences, Inc's operating cash flow?
Assembly Biosciences, Inc (ASMB) recorded an outflow of $41.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Assembly Biosciences, Inc's total assets?
Assembly Biosciences, Inc (ASMB) had $257.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Assembly Biosciences, Inc's capital expenditures?
Assembly Biosciences, Inc (ASMB) invested $66K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Assembly Biosciences, Inc spend on research and development?
Assembly Biosciences, Inc (ASMB) invested $64.8M in research and development during fiscal year 2025.
What is Assembly Biosciences, Inc's current ratio?
Assembly Biosciences, Inc (ASMB) had a current ratio of 5.22 as of fiscal year 2025, which is generally considered healthy.
What is Assembly Biosciences, Inc's debt-to-equity ratio?
Assembly Biosciences, Inc (ASMB) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Assembly Biosciences, Inc's return on assets (ROA)?
Assembly Biosciences, Inc (ASMB) had a return on assets of -2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Assembly Biosciences, Inc's P/E ratio?
Assembly Biosciences, Inc (ASMB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $458.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Assembly Biosciences, Inc's price-to-sales ratio?
Assembly Biosciences, Inc (ASMB) trades at 6.1x sales, its market capitalization divided by revenue of $74.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $458.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Assembly Biosciences, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Assembly Biosciences, Inc (ASMB) held $248.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $41.1M over that year. Dividing the one by the other, the reported balance equals about 72 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Assembly Biosciences, Inc's Altman Z-Score?
Assembly Biosciences, Inc (ASMB) has an Altman Z-Score of 1.98, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Assembly Biosciences, Inc's Piotroski F-Score?
Assembly Biosciences, Inc (ASMB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Assembly Biosciences, Inc's earnings high quality?
Assembly Biosciences, Inc (ASMB) reported a net loss of $6.1M while operations used $41.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Assembly Biosciences, Inc?
Assembly Biosciences, Inc (ASMB) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.